Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021, with a specific reporting date of March 10, 2021. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific securities transaction and does not contain consolidated financial statements or operational metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine acquisition of company securities by an executive.
Transaction Details and Management Commentary
The filing discloses two separate transactions executed on March 8, 2021, by Dr. H. Barron, Chief Scientific Officer and President, R&D. Both transactions occurred on the New York Stock Exchange (XNYS) at a price of $34.97 per American Depositary Share (ADS).
- Transaction 1: Acquisition of 1,204.71 ADSs within the GSK Executive Supplemental Savings Plan account.
- Transaction 2: Acquisition of 215 ADSs within the GSK 401(k) Plan account.
There is no management commentary, guidance, outlook, or discussion of risks and contingencies included in this specific filing.
Investor Verification Checklist
- Verify the total number of ADSs acquired by Dr. Barron on March 8, 2021 (1,419.71 total).
- Confirm the transaction price of $34.97 per ADS against the market price on the New York Stock Exchange for that date.
- Review the company's Form 20-F for the full fiscal year to obtain actual revenue, profit, and cash flow data, as this Form 6-K does not contain such figures.